GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

ClinicalTrials.gov ID: NCT02224703

Public ClinicalTrials.gov record NCT02224703. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 29, 2026, 8:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.

Study identification

NCT ID: NCT02224703
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Jazz Pharmaceuticals; Industry
Enrollment: 199 participants

Conditions and interventions

Conditions

Interventions

GWP42003-P Drug
Placebo Control Drug

Drug

Eligibility (public fields only)

Age range: 2 Years to 18 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 13, 2015 (Actual)
Primary completion: Apr 9, 2018 (Actual)
Completion: Apr 9, 2018 (Actual)
Last update posted: Sep 28, 2022

2015 – 2018

United States locations

U.S. sites: 23
U.S. states: 20
U.S. cities: 23

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35233	—
Not listed	Little Rock	Arkansas	72202	—
Not listed	Los Angeles	California	90027	—
Not listed	Sacramento	California	95816	—
Not listed	Hartford	Connecticut	06106	—
Not listed	Miami	Florida	33155	—
Not listed	Savannah	Georgia	31404	—
Not listed	Chicago	Illinois	60611	—
Not listed	Lexington	Kentucky	40536-0284	—
Not listed	Louisville	Kentucky	40202	—
Not listed	Saint Paul	Minnesota	55102	—
Not listed	St Louis	Missouri	63141	—
Not listed	Omaha	Nebraska	68106	—
Not listed	Lebanon	New Hampshire	03756	—
Not listed	Buffalo	New York	14203	—
Not listed	Chapel Hill	North Carolina	27599	—
Not listed	Portland	Oregon	97239	—
Not listed	Philadelphia	Pennsylvania	19104-4399	—
Not listed	Charleston	South Carolina	29425	—
Not listed	Austin	Texas	78723	—
Not listed	Fort Worth	Texas	76104	—
Not listed	Richmond	Virginia	23298-0211	—
Not listed	Seattle	Washington	98105	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02224703, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 28, 2022 · Synced Oct 29, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02224703 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →